The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be
| Study Title | A Phase 2a, Randomized, Placebo-Controlled, Double-Blind Multiple Ascending Dose Study in Patients with Cystic Fibrosis Carrying the 3849 +10 Kb C->T Mutation to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 |
|---|---|
| Study Drug | SPL84 |
| Type of Study Drug | Genetic therapy |
| Study Phase | 2a |
| Study Sponsor | SpliSense |
Link in registry(ies) | https://clinicaltrials.gov/study/NCT06429176 |
| Participating ECFS-CTN sites | Please contact ecfs-ctn@uzleuven.be for most recent sitelist |
| Age | Adult patients |